Outcome of Intravitreal Triamcinolone in Uveitis

Kok, Howe Sen; Lau, Chun Ho; Maycock, Nick; McCluskey, Peter; Lightman, Susan

doi:10.1016/j.ophtha.2005.06.009

Cited by 207 publications

(152 citation statements)

References 54 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…Kok et al, 4 also using 4 mg triamcinolone, found similar levels of IOP elevation; 34% of eyes developed IOP of 30 mmHg or higher and 11% an IOP of 40 mmHg or higher. This contrasts with Jonas et al, 19 who showed that only 5.5% of patients had an IOP above 35 mmHg and 1.8% above 40 mmHg.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Ocular morbidity associated with intravitreal triamcinolone acetonide

Konstantopoulos¹,

Williams²,

Newsom³

et al. 2006

Eye

View full text Add to dashboard Cite

Aim To report on the complications associated with the use of intravitreal triamcinolone acetonide (IVTA) in a tertiary referral hospital setting. Materials and methods A retrospective case series review of all IVTA injections carried out over a period of 30 months. Results One hundred and thirty IVTA injections were performed; nine with limited local follow-up were excluded. Thus, 121 injections (108 patients, 114 eyes) were included in the study. Triamcinolone (4 mg) was used in all cases. Indications were diabetic macular oedema (n ¼ 41 eyes), retinal vein occlusions (n ¼ 27), postoperative cystoid macular oedema (n ¼ 24), exudative age-related macular degeneration (n ¼ 16), and others (n ¼ 6). No intraoperative complications were recorded. Postoperative intraocular pressure (IOP) readings of 22, 28, 35, and 40 mmHg or higher were recorded in 46.5, 29.8, 12.3, and 7.9% of eyes, respectively. IOP elevation was treated with antiglaucoma medication in all but one eye (0.9%) that required trabeculectomy and one (0.9%) that required vitrectomy with cataract extraction for suspected phacoanaphylactic glaucoma. Two eyes (1.8%) developed retinal detachment; both had previously been treated for retinal breaks. One eye (0.9%) developed culture-positive endophthalmitis. Conclusions Significant morbidity is associated with IVTA injection; clinicians should be aware when considering treatment options.

show abstract

Section: Discussionmentioning

confidence: 82%

“…[1][2][3][4] In the past few years, there has been a remarkable interest in its use. This is demonstrated by an increasing number of publications; Pubmed search of 'intravitreal triamcinolone' resulted in 145 publications during the year 2005 compared to 81 during 2004 and 50 for the year before.…”

Section: Introductionmentioning

confidence: 99%

Ocular morbidity associated with intravitreal triamcinolone acetonide

Konstantopoulos¹,

Williams²,

Newsom³

et al. 2006

Eye

View full text Add to dashboard Cite

show abstract

“…1,2 Treatments include oral or periocular corticosteroids, sometimes given in combination with oral carbonic anhydrase inhibitors, 3 immune-modulating drugs, such as anti-TNF-a therapy [4][5][6] and intravitreally administered triamcinolone (TA). 7,8 Macular oedema in the setting of uveitis, as also for diseases, such as diabetic retinopathy or retinal vein occlusions (RVOs), arises due to a disruption of the blood-retinal barrier, with consecutive exudation and accumulation of serous fluid. 9 Evidence exists that VEGF is not only involved in the pathogenesis of CME in diabetes, RVO, but also in intraocular inflammatory diseases.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab

Weiß

Steinbrugger

Weger

et al. 2009

Eye

View full text Add to dashboard Cite

“…Intravitreal TA may reduce macular oedema and improve visual acuity, [1][2][3][4][5][6] and posterior subtenon TA injections have been suggested for the treatment of inflammation in uveitic eyes. 2,3,[7][8][9] However, such injections carry a considerable risk for intraocular pressure (IOP) elevation and cataract formation in both of these conditions.…”

Section: Introductionmentioning

confidence: 99%

Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis

Roesel

Gutfleisch

Heinz

et al. 2008

Eye

View full text Add to dashboard Cite

Purpose To evaluate the effect of orbital floor triamcinolone acetonide (OFTA) injections on inflammation and visual acuity in active non-infectious uveitis. Methods Monocentre, retrospective study in 94 eyes (86 patients) with acute non-infectious uveitis receiving a single OFTA (40 mg) injection. Outcome measures were anterior chamber (AC) and vitreous cell counts, laser flare photometry, best-corrected visual acuity (BCVA), and complications over a 6-month follow-up period. Results The number of patients with X1 þ cells in AC and vitreous was significantly lower after treatment than at baseline (each, Po0.01 at the follow-up examinations). The anti-inflammatory effect lasted for the 6-month follow-up period. Laser flare photometry values were also significantly lower than the baseline levels at 3 (Po0.01) and 6 (P ¼ 0.034) months. BCVA did not differ before and after treatment. Macular oedema was reduced in 27%, unchanged in another 59%, and worse in 14%. Within 6 months, ocular hypertension was observed in up to 8% and progressing cataract was noted in 29%. Conclusions OFTA injections improved AC and vitreous inflammation, but the effect on visual acuity and macular oedema was limited.

show abstract

Outcome of Intravitreal Triamcinolone in Uveitis

Cited by 207 publications

References 54 publications

Ocular morbidity associated with intravitreal triamcinolone acetonide

Ocular morbidity associated with intravitreal triamcinolone acetonide

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab

Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis

Contact Info

Product

Resources

About